Quick Answer
enGene Therapeutics Inc. reported Common Stock Shares Outstanding of 52.02 million shares for the year ending 2025.
- enGene Therapeutics Inc. showed an increase of +2.0% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), enGene Therapeutics Inc.'s Common Stock Shares Outstanding has grown by 7,713.3%.
- Historical annual values: Fiscal year 2025: 52.02 million shares | Fiscal year 2024: 50.98 million shares | Fiscal year 2023: 23.20 million shares | Fiscal year 2022: 665,767 shares.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: